Search for: "Endo Pharmaceutical"
Results 1 - 20
of 261
Sorted by Relevance
|
Sort by Date
20 May 2014, 10:07 am
Endo Pharmaceuticals Testosterone Therapy Drug Fortesta Faces Product Liability Lawsuit Endo Pharmaceuticals and the Prostrakan Group PLC were hit with a product liability lawsuit in a Pennsylvania court in early May for their testosterone therapy gel, Fortesta. [read post]
6 May 2019, 9:58 pm
Noonan -- Last Friday, the Federal Circuit affirmed a decision by the District Court that Defendants Actavis LLC and Teva Pharmaceuticals did not show by clear and convincing evidence that the claims asserted by Endo Pharmaceuticals Inc. and Mallinckrodt LLC were obvious, in Endo Pharmaceuticals Inc. v. [read post]
8 Apr 2014, 9:59 pm
Actavis, Inc. and Endo Pharmaceuticals Inc. v. [read post]
1 Apr 2019, 9:59 pm
By Donald Zuhn -- Last week, in Endo Pharmaceuticals Inc. v. [read post]
26 Feb 2014, 11:18 am
Under the terms of the agreement, Endo Pharmaceuticals will pay a total of $20.8 million in penalties. [read post]
27 Jun 2011, 11:02 am
Endo Pharmaceuticals today issued a voluntary nationwide consumer level recall of Endocet® (oxycodone/acetaminophen, USP) Tablets, 10 mg/325 mg 100 count bottles, NDC 60951-712-70, Lot # 402415NV and #402426NV. [read post]
6 Apr 2018, 6:38 am
In continuing coverage, TIME reports Endo Pharmaceuticals announced that it is voluntarily withdrawing Opana ER (oxymorphone hydrochloride) from the market. [read post]
9 Dec 2015, 9:59 pm
The '737 patent, which is assigned to Endo Pharmaceuticals Inc., is directed to methods of using... [read post]
16 Sep 2021, 12:57 pm
In its settlement with the state and counties, Endo and its subsidiaries, including Par Pharmaceutical, have been severed from the trial. [read post]
28 Feb 2014, 8:09 am
Endo Pharmaceuticals Pays Settlement for Off-Label Marketing of Lidoderm Pain Patch Endo Health Solutions Inc and its subsidiary Endo Pharmaceuticals have agreed to pay $171.9 million to settle False Claims allegations for off-label marketing of their pain patch, Lidoderm. [read post]
16 Apr 2021, 5:52 am
Endo Pharmaceuticals keep important evidence out of discovery. [read post]
1 Apr 2016, 5:30 am
The post FTC charges Endo Pharmaceuticals with antitrust violations for pay for delay patent settlements appeared first on IPWatchdog.com | Patents & Patent Law. [read post]
7 Sep 2021, 2:35 pm
The post In the News: New York State Files Motion Asking Judge to Render Default Judgement Against Endo Pharmaceuticals appeared first on Simmons Hanly Conroy. [read post]
7 May 2014, 8:03 am
Endo Agrees to $830 Million to Settle Transvaginal Mesh Claims On Wednesday, April 30th, Endo Pharmaceuticals agreed to settle the lawsuits in their transvaginal mesh multidistrict litigation (MDL) for $830 million. [read post]
21 Mar 2014, 8:40 am
Endo Set to Begin Transvaginal Mesh Personal Injury Trial as Bellwether Cases Scheduled A federal judge has set bellwether trial dates for the multidistrict litigation against Endo Pharmaceuticals and their transvaginal mesh devices. [read post]
10 Aug 2017, 11:28 am
Endo Pharmaceuticals, the owner of American Medical System (AMS) agreed to another $775 million to settle vaginal mesh injury lawsuits. [read post]
11 Apr 2011, 4:44 am
The deal is the third for Endo Pharmaceuticals in 12 months, and will add to the drug maker's treatments for urology and pain. [read post]
3 Oct 2014, 11:04 am
Endo Pharmaceuticals Reaches Settlement Agreement with Transvaginal Mesh Victims On Tuesday, September 30th, Endo International Plc stated that the medical device manufacturer had agreed to a settlement involving 20,000 transvaginal mesh personal injury claims, ending all of the cases against its American Medical Systems unit, which were going to trial in a multidistrict litigation (MDL). [read post]
18 Jan 2022, 2:29 pm
” Upon paying the settlement amount, Endo and two of its subsidiaries, Endo Pharmaceuticals Inc. and Endo Health Solutions Inc., will fully resolve Florida’s pending opioid-related claims. [read post]
28 Oct 2021, 7:40 am
As the sprawling New York State opioid trial heads into the last week of October, attention has shifted toward a court-commissioned referee report recommending sanctions against the defense law firm Arnold & Porter Kaye Scholer (APKS), which represented Endo Pharmaceuticals in the ongoing case. [read post]